PubHive wins 2026 AI-driven pharmacovigilance award

PubHive has been named Best AI-Driven Pharmacovigilance Platform 2026 in the SME Managing Director of the Year Awards. The recognition spotlights the company’s Human-in-the-Loop AI approach for literature monitoring, safety review, and traceable pharmacovigilance workflows.

Why it matters: - Pharmacovigilance teams are dealing with rising volumes of scientific literature and safety information. - PubHive’s approach is built to keep AI assistance inside a controlled review process, which matters for regulated life sciences work. - The award highlights growing demand for tools that combine automation with traceability, oversight, and audit-ready records.

What happened: - PubHive was named “Best AI-Driven Pharmacovigilance Platform 2026” in the SME Managing Director of the Year Awards. - The award recognizes PubHive’s AI-powered SaaS platform for scientific literature and safety information management. - The company said the recognition reflects its focus on more connected, structured, and transparent pharmacovigilance workflows. - Raj Vaghela, Founder and CEO of PubHive Ltd., said the company is focused on reducing operational complexity without removing scientific oversight from safety decisions.

The details: - PubHive Navigator™ combines literature monitoring, safety review, signal activities, aggregate reporting support, and scientific evidence management in one environment. - The platform supports global and local literature monitoring, ICSR review, signal detection and management, aggregate reporting workflows, reviewer assignment, quality control, dashboards, and audit-ready traceability. - PubHive’s Human-in-the-Loop AI-Assisted Review supports screening, classification, prioritisation, and evidence assessment while qualified professionals make final safety decisions. - The platform maintains evidence, reviewer activity, decisions, and follow-up actions in structured workflows. - Key capabilities include AI-assisted safety review, connected safety evidence, global and local oversight, signal and aggregate reporting support, reviewer assignment and quality control, operational visibility and deadlines, and traceable decision-making. - The company said the system is designed for regulated life sciences environments. - PubHive said its broader platform also supports Medical Affairs, scientific literature monitoring, evidence management, and regulatory workflows. - PubHive said its website is more information, and demo requests are available at book a demo. - The company listed media contact as hello@pubhive.com.

Between the lines: - The award suggests the market is valuing AI tools that assist reviewers rather than replace them. - PubHive is positioning itself around controlled automation, which can be more attractive in safety-critical settings than fully automated systems. - The emphasis on connected workflows points to a broader industry problem: fragmented tools can make safety review harder to track and audit.

What’s next: - PubHive said it will continue investing in AI-assisted review, scientific literature intelligence, and connected pharmacovigilance workflows. - The company plans to keep developing Human-in-the-Loop AI applications that reduce repetitive work and improve operational visibility. - PubHive is also focused on expanding connected, configurable, and compliance-ready technology for modern pharmacovigilance operations.

The bottom line: - PubHive is betting that the future of pharmacovigilance AI is not full automation, but faster review inside a tightly governed workflow.